Analyst Price Target is $6.67
▲ +262.32% Upside Potential
This price target is based on 3 analysts offering 12 month price targets for Cognition Therapeutics in the last 3 months. The average price target is $6.67, with a high forecast of $9.00 and a low forecast of $5.00. The average price target represents a 262.32% upside from the last price of $1.84.
Current Consensus is
Buy
The current consensus among 3 contributing investment analysts is to buy stock in Cognition Therapeutics. This Buy consensus rating has held steady for over two years.
Cognition Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of small molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina. Its lead product candidate is CT1812, an orally delivered molecule modulator designed to penetrate the blood-brain barrier and bind selectively to the S2R complex for the treatment of Alzheimer's disease. The company is also developing COG0201 SHINE, a randomized double-blind and placebo-controlled for mild-to-moderate AD and is in phase II clinical trial. Its product pipeline also includes CT2168 for Synucleinopathies; and CT2074 for dry age-related macular degeneration. The company was incorporated in 2007 and is headquartered in Purchase, New York.
Read More